These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 18954626)

  • 1. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients.
    Testa L; Van Gaal WJ; Bhindi R; Biondi-Zoccai GG; Abbate A; Agostoni P; Porto I; Andreotti F; Crea F; Banning AP
    J Thorac Cardiovasc Surg; 2008 Oct; 136(4):884-93. PubMed ID: 18954626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
    Carrier M; Ménasché P; Levy JH; Newman MF; Taylor KM; Haverich A; Chen JC; Shernan SK; Van de Werf F; van der Laan M; Todaro TG; Adams PX; Verrier ED
    J Thorac Cardiovasc Surg; 2006 Feb; 131(2):352-6. PubMed ID: 16434264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.
    Granger CB; Mahaffey KW; Weaver WD; Theroux P; Hochman JS; Filloon TG; Rollins S; Todaro TG; Nicolau JC; Ruzyllo W; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1184-90. PubMed ID: 12925454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.
    ; Armstrong PW; Granger CB; Adams PX; Hamm C; Holmes D; O'Neill WW; Todaro TG; Vahanian A; Van de Werf F
    JAMA; 2007 Jan; 297(1):43-51. PubMed ID: 17200474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial.
    Mahaffey KW; Granger CB; Nicolau JC; Ruzyllo W; Weaver WD; Theroux P; Hochman JS; Filloon TG; Mojcik CF; Todaro TG; Armstrong PW;
    Circulation; 2003 Sep; 108(10):1176-83. PubMed ID: 12925455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
    Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
    Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pexelizumab and its role in the treatment of myocardial infarction and in coronary artery bypass graft surgery: a review.
    Patel JA; Ghatak SB
    Recent Pat Cardiovasc Drug Discov; 2008 Jun; 3(2):145-52. PubMed ID: 18537766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
    Verrier ED; Shernan SK; Taylor KM; Van de Werf F; Newman MF; Chen JC; Carrier M; Haverich A; Malloy KJ; Adams PX; Todaro TG; Mojcik CF; Rollins SA; Levy JH;
    JAMA; 2004 May; 291(19):2319-27. PubMed ID: 15150203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview.
    Mahaffey KW; Van de Werf F; Shernan SK; Granger CB; Verrier ED; Filloon TG; Todaro TG; Adams PX; Levy JH; Hasselblad V; Armstrong PW
    Am Heart J; 2006 Aug; 152(2):291-6. PubMed ID: 16875911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior coronary artery bypass graft patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
    Welsh RC; Granger CB; Westerhout CM; Blankenship JC; Holmes DR; O'Neill WW; Hamm CW; Van de Werf F; Armstrong PW;
    JACC Cardiovasc Interv; 2010 Mar; 3(3):343-51. PubMed ID: 20298996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
    Smith PK; Carrier M; Chen JC; Haverich A; Levy JH; Menasché P; Shernan SK; Van de Werf F; Adams PX; Todaro TG; Verrier E
    Ann Thorac Surg; 2006 Sep; 82(3):781-8; discussion 788-9. PubMed ID: 16928483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients.
    Haverich A; Shernan SK; Levy JH; Chen JC; Carrier M; Taylor KM; Van de Werf F; Newman MF; Adams PX; Todaro TG; van der Laan M; Verrier ED
    Ann Thorac Surg; 2006 Aug; 82(2):486-92. PubMed ID: 16863750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge data.
    Weiss ES; Chang DD; Joyce DL; Nwakanma LU; Yuh DD
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):503-11, 511.e1-3. PubMed ID: 18329460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery.
    Mathew JP; Shernan SK; White WD; Fitch JC; Chen JC; Bell L; Newman MF
    Stroke; 2004 Oct; 35(10):2335-9. PubMed ID: 15331798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
    Whellan DJ; Tricoci P; Chen E; Huang Z; Leibowitz D; Vranckx P; Marhefka GD; Held C; Nicolau JC; Storey RF; Ruzyllo W; Huber K; Sinnaeve P; Weiss AT; Dery JP; Moliterno DJ; Van de Werf F; Aylward PE; White HD; Armstrong PW; Wallentin L; Strony J; Harrington RA; Mahaffey KW
    J Am Coll Cardiol; 2014 Mar; 63(11):1048-57. PubMed ID: 24211500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pexelizumab -- a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass.
    Fleisig AJ; Verrier ED
    Expert Opin Biol Ther; 2005 Jun; 5(6):833-9. PubMed ID: 15952913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction.
    Mills JS; Mahaffey KW; Lokhnygina Y; Nicolau JC; Ruzyllo W; Adams PX; Todaro TG; Armstrong PW; Granger CB;
    Coron Artery Dis; 2012 Mar; 23(2):118-25. PubMed ID: 22217457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Buller CE; Fu Y; Mahaffey KW; Todaro TG; Adams P; Westerhout CM; White HD; van 't Hof AW; Van de Werf FJ; Wagner GS; Granger CB; Armstrong PW
    Circulation; 2008 Sep; 118(13):1335-46. PubMed ID: 18779444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
    Smith PK; Shernan SK; Chen JC; Carrier M; Verrier ED; Adams PX; Todaro TG; Muhlbaier LH; Levy JH;
    J Thorac Cardiovasc Surg; 2011 Jul; 142(1):89-98. PubMed ID: 20880552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pexelizumab: a novel therapy for myocardial ischemia-reperfusion.
    Patel MR; Granger CB
    Drugs Today (Barc); 2005 Mar; 41(3):165-70. PubMed ID: 15883613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.